Truscreen Group

Truscreen Group Interest Coverage

The Interest Coverage Ratio of Truscreen Group (TRU.NZ) as of Oct 27, 2026 is -19.43. In the previous year, Interest Coverage Ratio was -79.02 — a change of -75.41% (higher).

Interest Coverage

-19.43

YoY

-75.41%

Last updated:

Interest Coverage Ratio of Truscreen Group is 2021 -19.43 . Interest Coverage Ratio of Truscreen Group was 2020 -79.02 . It decreases by -75.41% higher compared to the previous year.

The Truscreen Group Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2016
-52.59 NZD
Jan 1, 2017
-32.40 NZD
Jan 1, 2018
-11.18 NZD
Jan 1, 2019
-8.83 NZD
Jan 1, 2020
-79.02 NZD
Jan 1, 2021
-19.43 NZD
The Truscreen Group Interest Coverage history
YEARInterest CoverageYoY
-19.43-75.41%
-79.02+794.68%
-8.83-20.96%
-11.18-65.51%
-32.40-38.39%
-52.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Truscreen Group Stock analysis

What does Truscreen Group do? TruScreen Group Ltd develops and sells cancer detection devices and systems, focusing on cervical cancer screening. The company's AI-enabled device uses opto-electrical technology to detect precancerous and cancerous cervical changes in real-time through optical and electrical measurements of cervical tissue. The TruScreen device includes a Disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC), working together to resolve issues with cytology such as failed samples, poor patient follow-up, and patient discomfort. The company also addresses challenges with HPV testing by providing an alternative solution that avoids the need for laboratory infrastructure. The primary buyers of TruScreen's products are healthcare providers and clinics specializing in women's health, particularly those seeking efficient, real-time cervical screening solutions. The technology targets segments where traditional cytology and HPV testing face limitations, such as in resource-constrained settings or where patient adherence to follow-up is low. By offering a device that eliminates the need for supporting laboratory infrastructure, TruScreen appeals to providers looking to streamline cervical cancer screening processes. TruScreen's products are designed to replace or complement existing cervical screening methods, directly addressing the shortcomings of cytology and HPV testing. The company's focus on real-time detection and ease of use positions it as a solution for healthcare systems aiming to improve early cancer detection rates while reducing patient discomfort and logistical challenges associated with current screening practices. Truscreen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Truscreen Group stock

Interest Coverage Ratio of Truscreen Group is -19.43 in 2021.

Interest Coverage Ratio of Truscreen Group changed from -79.02 to -19.43, representing a -75.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Truscreen Group since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Truscreen Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Truscreen Group

All Key Metrics — Truscreen Group